Compugen secures licensing deal with Gilead for IL-18 protein antibody cancer program, with $60M upfront

Reynald Castañeda

Deputy Editor

Compugen is set to receive an upfront payment of $60 million from Gilead to kickstart an exclusive licensing deal for the biotech’s anti-interleukin-18 protein binding …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Compugen secures licensing deal with Gilead for IL-18 protein antibody cancer program, with $60M upfront

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test

Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Kennedy is confirmed to lead HHS, putting anti-vaccine advocate and drug industry skeptic atop US health programs

Hunger-suppressing biotech Aardvark raises $94M in IPO

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Com­pu­gen se­cures li­cens­ing deal with Gilead for IL-18 pro­tein an­ti­body can­cer pro­gram, with $60M up­front

Deputy Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Compugen secures licensing deal with Gilead for IL-18 protein antibody cancer program, with $60M upfront